Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas.

Next Previous
Search
Trial Profile

A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Antineoplastics; Cyclophosphamide; Doxorubicin; Granulocyte colony-stimulating factors; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ACE-1; ACT-1

    • Most Recent Events

    • 27 Feb 2019 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2018 Results (n=252) of pooled analysis of ACT-1 and ACT-2 comparing CHOP with A-CHOP to increase statistical power, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2012 Interim results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top